MeiraGTx Holdings plc is a pioneering force in the field of gene therapy, dedicated to crafting innovative treatments for serious diseases. With a focus on ocular diseases such as inherited retinal diseases and degenerative conditions, as well as neurodegenerative diseases and xerostomia, the company is advancing a diverse portfolio of therapies. Its research spans from early to mid-stage clinical trials, including efforts to combat achromatopsia, X-linked retinitis pigmentosa, and Parkinson’s disease. Founded in 2015 and headquartered in New York, MeiraGTx collaborates with Janssen Pharmaceuticals to push the boundaries of gene therapy for inherited retinal diseases.
Penny stocks represent an interesting investment opportunity. These stocks typically represent small companies or companies that are early in the development stages. But isn’t that how you make it big in the…
